CardioMEMS HF System

For pulmonary artery pressure monitoring

About the CardioMEMS HF System

The CardioMEMS™ HF System allows clinicians to monitor heart failure patients’ pulmonary artery (PA) pressure for proactive and actionable heart failure (HF) management and treatment. With early indications of worsening heart failure, you can remotely make adjustments to care to help slow the progression of heart failure, often before patients feel symptoms.

The CardioMEMS HF System is proven to:

Aid physicians in preventing worsening heart failure¹ and lowering mortality rates²
Significantly reduce heart failure hospitalizations^3,4
Improve quality of life in New York Heart Association (NYHA) Class III patients hospitalized for heart failure in the previous 12 months⁵

CardioMEMS HF System Product Information

CardioMEMS HF System Product Information

Indications

The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous 12 months. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Contraindications

The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

How It Works

Review how the CardioMEMS HF System gathers PA pressure data and transmits to the Merlin.net™ Patient Care Network.

Order CardioMEMS HF System

Find model numbers, specification sheets and sales support information for components of the CardioMEMS HF System.

CardioMEMS HF System Clinical Evidence

Multiple clinical trials have evaluated the safety and effectiveness of the CardioMEMS HF System. For a deep dive into the clinical data, visit the Clinical Evidence and Journal Article information.

Highlights from recent real-world data

62% reduction in heart failure hospitalizations⁷

62% reduction in heart failure hospitalizations

99.6% freedom from device or system related complications⁶

99.6% freedom from device or system related complications

60% reduction in heart failure hospitalization for HFpEF patients⁶

60% reduction in heart failure hospitalization for HFpEF patients

CardioMEMS HF System Education and Training

For safe and reliable HF management with the CardioMEMS HF System, we provide comprehensive educational resources. The following are designed to help you and your patients better understand patient selection, implantation and care.

Patient Selection

Patient Education

On-demand Webinars

Practice Management

Procedure Information

Manuals & Resources

Customer Service

This device is commercially available for use in select international markets.

References

Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357-65.
Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. https://dx.doi.org/10.1016/S0140-6736(11)60101-3
Shavelle D. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. Advance online publication. https://doi.org/10.1161/circheartfailure.119.006863
Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambula- tory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF) [published online ahead of print, 2020 Jun 27]. Eur J Heart Fail. 2020;10.1002/ejhf.1943. doi:10.1002/ejhf.1943

MAT-2108239 v1.0

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0